GlassScriptPhysician profile
Charles G Nesmith
NPI 1720263809
$11,957.65
in general payments reported to CMS, 2019-2025
43 companies · $1,936 in 2025
The $1,936 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $998 · 2021: $1,679 · 2022: $1,936 · 2023: $1,915 · 2024: $2,153 · 2025: $1,936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,941 · Education: $63.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,940.86 |
| Education | $63.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,348.28 | 2019-2025 | |
| Genzyme Corporation | $1,039.66 | 2022-2025 | |
| Pfizer INC. | $879.32 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $683.09 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Janssen Biotech, INC. | $610.98 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $585.30 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $508.08 | 2021-2024 | Zeposia |
| Medtronic, INC. | $448.65 | 2022 | |
| Phathom Pharmaceuticals, INC. | $370.69 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $370.28 | 2019-2024 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $363.48 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $316.18 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $293.74 | 2019-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $171.29 | 2023-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $163.29 | 2024-2025 | Terlivaz |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $162.95 | 2020-2023 | Epclusa |
| Medtronic USA, INC. | $148.19 | 2019 | |
| Lilly USA, LLC | $133.42 | 2023-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $123.17 | 2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $115.82 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $111.93 | 2019-2023 | Dificid, Zinplava |
| Janssen Scientific Affairs, LLC | $97.59 | 2020 | |
| Dova Pharmaceuticals | $95.71 | 2019 | |
| Organon LLC | $80.49 | 2021-2025 | Renflexis, Hadlima |
| Redhill Biopharma INC. | $77.12 | 2020-2022 | |
| Enterra Medical, INC. | $65.01 | 2025 | |
| Celltrion USA INC. | $63.60 | 2023-2024 | Yuflyma, Zymfentra |
| Aimmune Therapeutics, INC. | $53.53 | 2024-2025 | Vowst |
| Allergan, INC. | $53.22 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $50.84 | 2020-2023 | Rebyota |
| Romark Laboratories, Lc | $48.60 | 2019-2020 | |
| Amgen INC. | $45.89 | 2023 | Avsola, Amjevita |
| Daiichi Sankyo INC. | $42.94 | 2021-2023 | Injectafer |
| Alfasigma USA, INC. | $42.16 | 2020 | |
| Boston Scientific Corporation | $40.98 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $33.66 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $27.34 | 2024 | Givlaari |
| Ipsen Biopharmaceuticals, INC | $19.05 | 2024 | Iqirvo |
| Fresenius Kabi USA, LLC | $17.28 | 2023 | Idacio |
| Ucb, INC. | $16.94 | 2019 | |
| Merit Medical Systems INC | $15.43 | 2025 | Endomaxx Stent and Delivery System, Esophyx |
| Ethicon US, LLC | $11.49 | 2020 | |
| Endo Pharmaceuticals INC. | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Nesmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.